Antibiotics Pathway Legislation Gets Continued Push Despite FDA Moves
This article was originally published in The Pink Sheet Daily
Executive Summary
Twenty organizations sign letter to House and Senate members indicating creation of a limited-population antibiotic drug pathway still is necessary and FDASIA incentives are only a start.